– May 1, 2013
May 1, 2013
View Issues
Toward a Better Understanding of Aromatase Inhibitor-associated Musculoskeletal Symptoms
Arthralgias and associated symptoms are common among postmenopausal breast cancer patients treated with aromatase inhibitors.Aspirin and Melanoma Prevention: Data from the Women’s Health Initiative
In a large population of Caucasian women participating in the Womens Health Initiative Observational Study, those who used aspirin had a significantly lower risk of melanoma and increased duration of use was associated with incrementally greater protection.Targeted Therapy for Low-grade Serous Ovarian Cancer Shows Promise
Selumetinib, a selective MEK1/2 inhibitor, achieved objective responses in 15% of patients with recurrent low-grade serous ovarian cancer. The data are relevant as this uncommon tumor type is associated with general chemoresistance, frequent aberration in the MAPK pathway, and prolonged overall survival compared with its more common high-grade variant. Phase 3 trials are planned.Improving Transplant Outcomes for Patients without a Match
Carboplatin-pemetrexed doublet chemotherapy is effective primary treatment for patients with nonsquamous non-small cell lung cancer, but the applicability of standard dosing to older or more frail patients was uncertain.Finding the Right Dose of Carboplatin/Pemetrexed for Elderly Lung Cancer Patients
Carboplatin-pemetrexed doublet chemotherapy is effective primary treatment for patients with nonsquamous non-small cell lung cancer, but the applicability of standard dosing to older or more frail patients was uncertain.Pharmacology Watch: New Study on Chelation Therapy Proves Controversial
Chelation therapy for cardiovascular disease; statins and kidney injuries; chlorthalidone for hypertension; and FDA actions.Clinical Briefs in Primary Care Supplement